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Abstract We previously demonstrated that uridine adeno-
sine tetraphosphate (Up4A) induces potent and partially
endothelium-dependent relaxation in the healthy porcine
coronary microvasculature. We subsequently showed that
Up4A-induced porcine coronary relaxation was impaired
via downregulation of P1 receptors after myocardial infarc-
tion. In view of the deleterious effect of metabolic derange-
ment on vascular function, we hypothesized that the coro-
nary vasodilator response to Up4A is impaired in metabolic
derangement, and that the involvement of purinergic recep-
tor subtypes and endothelium-derived vasoactive factors
(EDVFs) is altered. Coronary small arteries, dissected from
the apex of healthy swine and swine 6 months after induc-
tion of diabetes with streptozotocin and fed a high-fat diet,
were mounted on wire myographs. Up4A (10
−9–10−5 M)-
induced coronary relaxation was maintained in swine with
metabolic derangement compared to normal swine, despite
impaired endothelium-dependent relaxation to bradykinin
and despite blunted P2X7 receptor and NO-mediated vaso-
dilator influences of Up4A. Moreover, a thromboxane-
mediated vasoconstrictor influence was unmasked. In con-
trast, an increased Up4A-mediated vasodilator influence
via P2Y1 receptors was observed, while, in response to
Up4A, cytochrome P450 2C9 switched from producing va-
soconstrictor to vasodilator metabolites in swine with met-
abolic derangement. Coronary vascular expression of A2A
and P2X7 receptors as well as eNOS, as assessed with real-
time PCR, was reduced in swine with metabolic derange-
ment. In conclusion, although the overall coronary vasodi-
lator response to Up4A was maintained in swine with met-
abolic derangement, the involvement of purinergic recep-
tor subtypes and EDVF was markedly altered, revealing
compensatory mechanisms among signaling pathways in
Up4A-mediated coronary vasomotor influence in the early
phase of metabolic derangement. Future studies are war-
ranted to investigate the effects of severe metabolic de-
rangement on coronary responses to Up4A.
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Introduction
Diabetes mellitus is the most prevalent endocrine disorder
worldwide, and diabetes mellitus and associated metabolic
derangement constitute an important risk factor for develop-
ment of cardiovascular disease including atherosclerosis and
diabetic heart disease. The latter is the consequence not only
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of proximal obstructive coronary artery disease but also of
coronary microvascular disease [1, 2]. Endothelial dysfunc-
tion is an important determinant of altered vascular reactivity
and plays a major role in the etiology of diabetes-induced
macrovascular and microvascular complications [3, 4]. This
endothelial dysfunction encompasses an imbalance between
the secretion of endothelium-derived relaxing factors (such as
NO and prostacyclin) and endothelium-derived constricting
factors (such as endothelin and thromboxane) [4, 5].
Uridine adenosine tetraphosphate (Up4A) was initially
identified as an endothelium-derived vasoconstrictor, exerting
its constrictor influence in various vascular beds [6–10]. The
vasoconstriction was shown to involve the generation of
thromboxane [11] and reactive oxygen species [12]. A subse-
quent study reported that Up4A-mediated vascular contraction
was enhanced in renal, basilar, and femoral arteries of DOCA-
salt-induced hypertensive rats compared to normal rats [9].
Moreover, Up4A-induced contraction was increased in renal
arteries from rats with type 2 diabetes through activation of the
cyclooxygenase-thromboxane pathway [13], suggesting that
disease states, including diabetes-associated metabolic de-
rangement [14] , may aggravate Up4A-media ted
vasoconstriction.
Similar to other extracellular nucleotides, Up4A exerts its
vasomotor influence by binding to purinergic receptors [15,
16]. The purinergic receptor family consists of P1 (adenosine
receptors) and P2 receptor subtypes that can be further divided
into P2X and P2Y receptors [17]. There is evidence from
rodent models and humans that vascular purinergic signaling
is altered in metabolic disorders [18]. The vasoconstrictor re-
sponse to ATP, a putative P2 receptor agonist [19], was in-
creased, while in preconstricted mesenteric arteries from rats
with diabetes, the vasodilator response to ATP was decreased
[20, 21]. Similarly, the vasodilation to ATP, UTP, and adeno-
sine was impaired in femoral arteries of patients with type 2
diabetes [22].
Contrary to the vasoconstrictor effect of Up4A in most
vascular beds [6–10], Up4A acts as a potent vasodilator in
the coronary microcirculation [15]. We recently demon-
strated that Up4A-induced coronary relaxation was
blunted in swine after myocardial infarction possibly via
downregulation of P1 receptors [23]. In the present study,
we tested the hypothesis that the coronary vasodilator re-
sponse to Up4A is also impaired in swine with metabolic
derangement (diabetes mellitus and dyslipidemia) and in-
vestigated the involvement of altered signaling through
purinergic receptor subtypes and endothelium-derived va-
soactive factors (EDVFs). Our findings surprisingly dem-
onstrate that, despite the presence of endothelial dysfunc-
tion, the coronary vasodilator response to Up4A was
maintained in metabolic derangement. However, the con-
tribution of purinergic receptor subtypes and endothelium-
derived factors was markedly altered.
Materials and methods
Animals
Diabetes was induced in 10 female swine (2–3 months old,
25.1 ± 1.2 kg) with intravenous injections of streptozotocin
(50mg/kg/day, Bioconnect, The Netherlands, AG-CN2-0046)
for three days. This dose of streptozotocin resulted in a stable
hyperglycemia, as evidenced by glucose levels of 19.5 ± 1.4
(week 1), 21.6 ± 2.9 (week 3), 18.8 ± 2.0 (week 18), and
18.7 ± 2.1 mmol/l (week 20). One to two weeks after diabetes
induction, a high-fat diet (25% saturated fats and 1% choles-
terol) was gradually introduced [3]. Swine were housed in
metabolic cages with ad libitum access to food for 1 h per
meal, twice daily for the entire 6-month study duration. The
diabetic status was regularly monitored by measurement of
glucose and ketone levels in urine and blood. At sacrifice,
swine with metabolic derangement weighed 104 ± 8 kg.
Five healthy female crossbred Yorkshire × Landrace swine,
purchased from the same breeder two weeks prior to sacrifice
and matched for age and weight to swine with metabolic de-
rangement (8–9 months old, 119 ± 5 kg), served as a control
group.
Blood and tissue sampling
At sacrifice, animals were sedated with an intramuscular in-
jection of Zoletil (Tiletamine/Zolazepam; 5 mg/kg) and
Xylazine (2.25 mg/kg), anesthetized with pentobarbital
(20 mg/kg/h i.v.) and artificially ventilated. Catheters were
inserted for arterial blood sampling [24]. The collected blood
samples were stored for later determination of lipids, glucose
and insulin levels. Following thoracotomy, hearts were
arrested and immediately excised and placed in cold, oxygen-
ated Krebs bicarbonate buffer solution.
Myograph studies
Left ventricular apices from female swine with metabolic de-
rangement (n = 10) and normal swine (n = 5) were collected at
the time of sacrifice. Additional apices were collected from 8
hearts of healthy swine (3 female + 5 unknown gender) ob-
tained from a local slaughterhouse. When the vascular re-
sponse to Up4A (Biolog Life Science, Germany, U008) in
the 8 female swine did not differ from the 5 swine of unknown
gender from the slaughterhouse, data were pooled into a single
control group (normal, n = 13), otherwise only data from
coronary small arteries of female swine were used.
Coronary small arteries (diameter ~ 150 μm) were dissect-
ed out from the apex of 7 swine with metabolic derangement
and 13 normal swine and stored overnight in cold, oxygenated
Krebs bicarbonate solution of the following composition
(mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4
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1.2, NaHCO3 25, and glucose 8.3; pH 7.4 [15, 25]. The next
day, coronary arteries were cut into segments of ~2 mm length
and mounted in microvascular myographs (Danish Myo
Technology) in separate 6 ml organ baths containing Krebs
bicarbonate solution aerated with 95% O2/5% CO2 and main-
tained at 37 °C. Changes in contractile force were recorded
with a Harvard isometric transducer. Following a 30-min sta-
bilization period, the internal diameter was set at a tension
equivalent to 0.9 times the estimated diameter at 100 mmHg
effective transmural pressure [15, 25]. At the end of the stabi-
lization period, the vessels were exposed to 30 mMKCl twice
to check the contractility. Endothelial integrity was verified by
observing relaxation to 10 nM substance P after
preconstriction with 100 nM of the stable thromboxane A2
analogue 9,11-dideoxy-11α,9α-epoxymethanoprostaglandin
F2α (U46619). Then, vessels were subjected to 100 mM
KCl to determine the maximal vascular contraction.
Thereafter, vessels were allowed to equilibrate in fresh
Krebs solution for 30 min before initiating different experi-
mental protocols [15, 25]. In experiments where the effect of
an antagonist on the response to Up4Awas assessed, antago-
nists were added to the organ baths 30 min before
preconstriction with U46619 and were present throughout
the experiments. Only one protocol was executed per vessel
segment, and, within one protocol, each vessel was obtained
from a different animal.
Experimental protocols
The coronary small arteries from both normal swine and swine
with metabolic derangement were subjected to increasing
Up4A concentrations (10
−9–10−5M). Since no vasoconstrictor
influence was observed in vessels from both normal swine and
swine with metabolic derangement (data not shown), vessels
were preconstricted with U46619 to study the vasodilator ef-
fect of Up4A and the signaling pathways involved.
To investigate the involvement of purinergic receptors in
Up4A-induced relaxation, preconstricted coronary small arteries
from both normal swine and swine with metabolic derangement
were exposed to increasing Up4A concentrations (10
−9–
10−5 M), in the absence and presence of the non-selective P1
receptor antagonist 8-phenyltheophylline (8PT, 10 μM, Sigma-
Aldrich, The Netherlands, P2278), the non-selective P2 receptor
antagonist pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic
acid (PPADS, 10 μM, Sigma-Aldrich, The Netherlands,
P178), and combined P1 and P2 receptor blockade [15, 23].
To assess the role of purinergic receptor subtypes, vessels were
tested in the absence and presence of adenosine A2A receptor
antagonis t SCH58261 (100 nM, Sigma-Aldr ich,
The Netherlands, S4568), P2X1 receptor antagonist MRS2159
(30 μM, Sigma-Aldrich, The Netherlands, M7684) [15, 23, 26],
P2X7 receptor antagonist A438079 (10 μM, Sigma-Aldrich,
The Netherlands, A9736) [27], P2Y1 receptor antagonist
MRS2179 (1 μM, Sigma-Aldrich, The Netherlands, M3808),
or P2Y6 antagonist MRS2578 (10 μM, Sigma-Aldrich,
The Netherlands, M0319) [15, 23]. Although the purinergic re-
ceptor blockers, in the concentrations employed in the present
study, predominantly block the receptor subtypes they were de-
signed for, it cannot be entirely excluded that other purinergic
receptors were, to some extent, also affected. Careful evaluation
of the selectivity profiles is therefore necessary to properly inter-
pret the results in the present study. MRS2159 has been shown
to block, in addition to P2X1 receptors, P2X2, P2X2/3, and P2Y1
receptors in 1321N1 cells [27] and P2X7 receptors in 1321N1
cells and erythrocytes [27, 28]. Moreover, while A438079, at
concentrations up to 100μM, has been shown to be selective for
P2X7 receptors as compared to P2X1, P2X2a, P2X2/3, P2X4,
P2Y1, and P2Y2 receptors in 1321N1 cells [29], other purinergic
receptor subtypes were not tested. MRS2179 was shown to
inhibit neither the response to UTP at the human P2Y2 and
P2Y4 receptors nor the response to UDP at the P2Y6 receptor,
and it was found to be 11-fold and 130-fold more selective for
P2Y1 receptors than for P2X1 and P2X3 receptors, respectively,
and to be inactive at rat P2X2 and P2X4 receptors in Xenopus
oocytes [30]. MRS2578, at concentrations up to 10 μM, did not
affect P2Y1, P2Y2, P2Y4, and P2Y11 receptor-mediated re-
sponses in 1321N1 cells [31]. Finally, SCH58261 was shown
to be 581-fold more selective for A2A than A2B receptors [32].
A subset of coronary small arteries was de-endothelialized,
preconstricted with 100 nM U46619, and exposed to increas-
ing Up4A concentrations (10
−9–10−5 M). Other endothelium-
intact coronary small arteries from both normal swine and
swine with metabolic derangement were preconstricted with
U46619 and exposed to increasingUp4A concentrations in the
absence and presence of the nitric oxide synthase (NOS) in-
hibitor LNAME (100 μM, Sigma-Aldrich, The Netherlands,
N5751), LNAME in combination with the cyclooxygenase
inhibi tor indomethacin (10 μM, Sigma-Aldrich,
The Netherlands, I7378) [15], or LNAME + indomethacin +
the cytochrome P450 2C9 (CYP 2C9) inhibitor sulfaphenazole
(10 μM, Sigma-Aldrich, The Netherlands, S0758) [15, 23].
Finally, the effect of thromboxane synthase inhibitor ozagrel
(10 μM, Sigma-Aldrich, The Netherlands, O1385) on the cor-
onary vasodilator response to Up4Awas studied in the absence
and presence of LNAME.
MRS2578 and indomethacin were firstly dissolved in
DMSO and further diluted in distilled water. Sulfaphenazole
was dissolved in ethanol and further diluted in distilled water.
Other drugs were dissolved in distilled water. PPADS and
MRS2159 were protected from light.
Quantitative real-time PCR analysis
Following dissection, endothelium-intact coronary small ar-
teries were snap-frozen in liquid nitrogen to be used for de-
tection of A2A, P2X1, P2X4, P2X7, P2Y1, P2Y2, P2Y4, and
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P2Y6 receptors mRNA. In addition, the expression of
endothelial NOS (eNOS) was measured [33]. Total RNA
was extracted from 5 to 7 frozen samples per group using a
Qiagen RNA kit. cDNAwas synthesized from 100 ng of total
RNA with iScript Reverse Transcriptase (Bio-Rad).
Quantitative real-time PCR (MyIQ, Bio-Rad) was performed
with SYBR Green (Bio-Rad) [15]. Target gene mRNA levels
were expressed relative to the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an
endogenous control [34]. Primer sequences are shown in
Table 1.
Data analysis and statistics
Data are presented as mean ± SEM. Statistical analysis of
plasma lipids, glucose and insulin was performed using an
unpaired two-tailed t test. Vascular relaxation responses to
Up4A were expressed as percentage of contraction to
U46619 [15]. The effects of drug treatment on Up4A re-
sponses were analyzed using two-way ANOVA for repeated
measures. Statistical significance was accepted when P < 0.05
(two-tailed).
Results
Characteristics of diabetes and metabolic derangement
Metabolic derangement was present six months after induc-
tion of diabetes with streptozotocin and start of a high-fat diet.
Plasma levels of glucose, total cholesterol, high density lipo-
protein (HDL), low density lipoprotein (LDL), and triglycer-
ides in swine with metabolic derangement were significantly
elevated as compared to normal swine, while insulin levels
were similar (Table 2). Fatty streaks were observed in the
proximal coronary arteries, but plaque burden never amounted
more than 10% of the vascular lumen; fatty streaks were not
observed in the coronary microvessels.
Vasoactive influence of Up4A on coronary vasculature
in swine with metabolic derangement
Up4A failed to elicit any vasoconstrictor response in coronary
small arteries from either normal swine or swine with
metabolic derangement (data not shown). Following
preconstriction with U46619, Up4A produced concentration-
dependent relaxation up to 100%, which was virtually identi-
cal between the two groups (Fig. 1). In contrast, bradykinin
(10−10–10−6 M)-induced endothelium-dependent relaxation in
coronary small arteries was impaired in swine with metabolic
derangement (−logEC50 8.61 ± 0.12 in normal (n = 6) vs
7.89 ± 0.19 in metabolic derangement (n = 5); P < 0.05).
Effect of metabolic derangement on function
and expression of purinergic receptor subtypes
Non-selective P1 receptor blockade with 8PT and, to a
lesser extent, non-selective P2 receptor blockade with
PPADS attenuated the coronary vasodilator response to
Up4A (Fig. 2). These responses were however not different
between the two groups. In contrast, while the effect of
combined administration of 8PT and PPADS was similar
to the effect of 8PT alone in normal swine (Fig. 2a), the
effect of 8PT and PPADS was significantly greater than the
effect of 8PT alone in swine with metabolic derangement
with unmasking of a mild vasoconstrictor response to
Up4A (Fig. 2b).
A2A receptor blockade resulted in attenuation of the re-
sponse to Up4A that was comparable with the attenuation by
8PT and was not different between coronary small arteries
from normal swine and swine with metabolic derangement
(Fig. 3a, f), despite slightly lower A2A mRNA expression
Table 1 Primer information
Genes Sequence Size
Sense Antisense
A2A 5′-ATGTTGGGCTGGAATAGCTG-3′ 5′-CACGGAGTTGGTGTGAGAGA-3′ 426 bp
P2X1 5′-TTGAACCCCATTTCTTCCTG-3′ 5′-AGTGCACCACACATCTGCTC-3′ 248 bp
P2X4 5′-TGTCCCCAGGCTACAATTTC-3′ 5′-GGCAGCTTTTTCTCCCTTCT-3′ 373 bp
P2X7 5′-CTTTTGCACCTTGAGCTTCC-3′ 5′-TCCATGCTAAGGGATTCTGG-3′ 152 bp
P2Y1 5′-TTCCTGACTTGCATCAGTGC-3′ 5′-CAGTGCCCGAGTAGAAGAGG-3′ 157 bp
P2Y2 5′-GTGGCCTACAGCTTGGTCAT-3′ 5′-GCGTGCGGAAGGAGTAGTAG-3′ 235 bp
P2Y4 5′-GACTGCCGGTTTAATGAGGA-3′ 5′-AGGAAAAGGACGCTGCAGTA-3′ 302 bp
P2Y6 5′-CTGCTCTTGCCACCTGTGTA-3′ 5′-AGGTTGGCGTAGAACAGGAA-3′ 251 bp
eNOS 5′-CTCTCCTGTTGGCCTGACCA-3′ 5′-CCGGTTACTCAGACCCAAGG-3′ 151 bp
GAPDH 5′-TCGGAGTGAACGGATTTG-3′ 5′-CCTGGAAGATGGTGATGG-3′ 219 bp
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levels in coronary small arteries of metabolic derangement
(Fig. 4). P2X1 receptor blockade with MRS2159 attenuated
Up4A-induced relaxation to a similar extent in coronary small
arteries from normal swine and swine with metabolic derange-
ment (Fig. 3b, g), which was consistent with the unaltered
P2X1 mRNA expression between the two groups (Fig. 4).
P2X7 receptor blockade with A438079 attenuated the vasodi-
lator response to Up4A in coronary small arteries from normal
swine (Fig. 3c) but not from swine with metabolic derange-
ment (Fig. 3h), which was consistent with the reduced coro-
nary P2X7 mRNA expression in swine with metabolic de-
rangement (Fig. 4). In contrast, P2Y1 blockade with
MRS2179 attenuated Up4A-induced relaxation only in coro-
nary small arteries from swine with metabolic derangement
(Fig. 3i) but not from normal swine (Fig. 3d) despite the un-
altered mRNA expression of P2Y1 receptors (Fig. 4). The
attenuation by P2Y6 blockade with MRS2578 of Up4A-in-
duced vasorelaxation and the P2Y6 mRNA expression were
comparable between coronary small arteries of normal swine
and swine with metabolic derangement (Figs. 3e, j and 4).
Role of endothelium in Up4A-induced coronary relaxation
Endothelial denudation, as confirmed by the absence of a
vasodilator response to substance P (data not shown), attenu-
ated the vasodilator response to Up4A in coronary small arter-
ies from normal swine (Fig. 5a) but not from swine with met-
abolic derangement (Fig. 5d). Similarly, eNOS inhibition with
LNAME attenuated the response to Up4A in vessels from
normal swine (Fig. 5a) but not from swine with metabolic
derangement (Fig. 5d), which was consistent with the reduced
eNOS expression in swine with metabolic derangement, from
0.52 ± 0.14 in normal to 0.19 ± 0.03 inmetabolic derangement
(P < 0.05). Additional COX-inhibition with indomethacin had
no effect in coronary small arteries from either normal swine
(Fig. 5b) or swine with metabolic derangement (Fig. 5e). In
the presence of combined eNOS and COX blockade, inhibi-
tion of CYP 2C9 with sulfaphenazole enhanced the relaxation
to Up4A in coronary small arteries from normal swine,
(Fig. 5c), whereas in vessels from swine with metabolic de-
rangement, sulfaphenazole attenuated the vasorelaxation to
Up4A (Fig. 5f). These findings suggest that CYP 2C9
switches from the production of vasoconstrictor metabolites
in normal swine to vasodilator metabolites in swine with met-
abolic derangement.
The thromboxane synthase inhibitor ozagrel had no effect
on Up4A-induced relaxation in coronary small arteries from
either normal swine (Fig. 6a) or swine with metabolic de-
rangement (Fig. 6c). However, while in normal swine, in the
presence of LNAME, ozagrel failed to significantly affect
Up4A-induced relaxation of coronary small arteries (Fig. 6b,
P = 0.17), ozagrel significantly enhanced the vasodilator re-
sponse to Up4A in coronary small arteries from swine with
metabolic derangement (Fig. 6d).
Discussion
The present study is the first to investigate the coronary vas-
cular effects of the dinucleotide Up4A in a large animal model
of metabolic derangement. The main findings were that (1)
Table 2 Plasma and lipid
parameters of variables Normal (n = 5) Metabolic derangement (n = 10)
Insulin (pmol/l) 2.50 ± 0.48 3.42 ± 0.92
Glucose (mmol/l) 5.32 ± 0.77 16.58 ± 1.07*
Cholesterol (mmol/l) 2.22 ± 0.34 16.45 ± 2.10*
HDL (mmol/l) 0.88 ± 0.11 3.74 ± 0.59*
LDL (mmol/l) 1.38 ± 0.27 14.35 ± 1.98*
Triglycerides (mmol/l) 0.15 ± 0.04 0.63 ± 0.11*
HDL high density lipoprotein, LDL, low density lipoprotein. Values are mean ± SEM; *P < 0.05 vs. normal
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Fig. 1 Vasodilator effects of Up4A. Shown are concentration responses
to Up4A (10
−9–10−5 M) in coronary small arteries preconstricted with
U46619 (100 nM) from normal swine (n = 13) and swine with
metabolic derangement (n = 10). Values are mean ± SEM
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Up4A-induced relaxation was not altered in coronary small
arteries isolated from swine with metabolic derangement as
compared to normal swine, despite the presence of endothelial
dysfunction; (2) combined P1 and P2 receptor blockade had
an additive effect in swine with metabolic derangement but
not in normal swine; (3) there was a shift in involvement of
purinergic receptors from P2X7 receptors in normal swine to
P2Y1 receptors in swine with metabolic derangement; (4) en-
dothelial denudation as well as eNOS inhibition attenuated the
response to Up4A in normal swine but not in swine with met-
abolic derangement, and eNOS inhibition unmasked throm-
boxane production in swine with metabolic derangement, but
not normal swine, in response to Up4A; and (5) CYP 2C9
metabolites exerted a vasoconstrictor influence in response
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Fig. 2 Effects of non-selective purinergic receptor blockade on Up4A-
induced relaxation. Shown are concentration responses to Up4A (10
−9–
10−5 M) in porcine coronary small arteries in the control vessels (normal,
n = 13; metabolic derangement, n = 7) and in the presence of 10 μMnon-
selective P1 receptor antagonist 8PT (normal, n = 5; metabolic derange-
ment, n = 6), in the presenc e of 10 μM non-selective P2 receptor
antagonist PPADS (normal, n = 5; metabolic derangement, n = 7) as well
as in the presence of combined 8PTand PPADS (normal, n = 6; metabolic
derangement, n = 4). Values are mean ± SEM. *P < 0.05 vs. Control;
†P < 0.05 vs. PPADS; ‡P < 0.05 vs. 8PT; §P < 0.05 effect of 8PT +
PPADS in metabolic derangement differs from that in normal
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Fig. 3 Involvement of purinergic receptor subtypes in Up4A-induced
relaxation. Shown are concentration responses to Up4A (10
−9–10−5 M)
in porcine coronary small arteries in control vessels (normal, n = 13;
metabolic derangement, n = 7) and in the presence of 100 nM A2A
receptor antagonist SCH58261 (normal (n = 8, panel a); metabolic
derangement (n = 7, panel f)); in the presence of 30 μM P2X1 receptor
antagonist MRS2159 (normal (n = 6, panel b); metabolic derangement
(n = 7, panel g)); in the presence of 10 μM P2X7 receptor antagonist
A438079 (normal (n = 7, panel c); metabolic derangement (n = 6, panel
h)); in the presence of 1 μMP2Y1 receptor antagonist MRS2179 (normal
(n = 9, panel d); metabolic derangement (n = 7, panel i)); and in the
presence of 10 μM P2Y6 receptor antagonist MRS2578 (normal (n = 6,
panel e); metabolic derangement (n = 6, panel j)). For the sake of
comparison, non-selective P1 blockade with 8PT (normal, n = 10; meta-
bolic derangement, n = 6) is shown as dotted line in panels a and f, while
non-selective P2 blockade with PPADS (normal, n = 5; metabolic de-
rangement, n = 7) is shown as dotted line in panels b, c, d, e, g, h, i,
and j. Values are mean ± SEM. *P < 0.05 vs. control
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to Up4A in normal swine but exerted a vasodilator influence
on the Up4A responses in swine with metabolic derangement.
The implications of these findings will be discussed below.
The dinucleotide Up4A was initially identified as a novel
endothelium-derived vasoconstrictor [6]. Subsequent studies
demonstrated that Up4A induces vascular contraction in most
vascular beds, including mouse renal arterioles [35], mouse
aortas [11, 36, 37], rat aortas [12], rat mesenteric arteries [9],
rat pulmonary arteries [7], and rat renal arteries [6], particular-
ly in the presence of diabetes [13]. In addition to its vasocon-
strictor effects in most vascular beds under basal tone, Up4A
can act as a vasodilator when vascular tone is elevated in the
rat aortas and rat perfused kidney [12, 38]. In contrast, we
previously found that Up4A is purely a vasodilator in the
healthy porcine coronary microcirculation, without any vaso-
constrictor activity [15]. We also recently found that this va-
sodilator response to Up4A is reduced after myocardial infarc-
tion in coronary microvessels supplying the remote myocar-
dium [23]. Surprisingly, we did not observe any blunting of
the coronary vasodilator response to Up4A in swine with met-
abolic derangement as compared to normal swine in the pres-
ent study (Fig. 1), despite evidence of endothelial dysfunction
as indicated by the blunted endothelium-dependent relaxation
to bradykinin both at 2 months in our previous study [3] as
well as 6 months of metabolic derangement in the present
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Fig. 4 Expression profile of various purinergic receptor subtypes in
normal and metabolic derangement. mRNA levels of each gene were
normalized to that of housekeeping gene GAPDH. Data in the normal
group are identical to those published in [23] but were performed in
parallel to the experiments in the vessels obtained from animals with
metabolic derangement. Values are mean ± SEM. *P < 0.05 vs. normal
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study. However, we did observe marked changes in the con-
tribution of various purinergic receptor and endothelial medi-
ators to the relaxation produced by Up4A.
In coronary small arteries from healthy swine, the vasodi-
lator effect of Up4A is principally mediated through P1 re-
ceptors, although the P2X1 and P2Y1 receptors also contrib-
ute in vessels of approximately 150 μm in diameter [23] but
not in vessels of 250–300 μm [15]. In coronary small arteries
from swine with metabolic derangement, expression of the
A2A receptor was slightly reduced, but a major part of the
vasodilator effect of Up4A was still exerted through this
purinergic P1 receptor subtype. The effect of combined P1
and P2 receptor blockade was markedly enhanced in the cor-
onary small arteries from swine with metabolic derangement,
even unmasking a modest vasoconstrictor effect in response
to Up4A, suggesting that the P2 receptor subtypes involved in
response to Up4A may differ between the two groups. Indeed,
we found that both the expression and contribution of P2X7
receptors to Up4A-induced relaxation were decreased. In con-
trast, the contribution of P2Y1 receptors was increased in
coronary small arteries from swine with metabolic derange-
ment, even though expression of the P2Y1 receptors was not
altered. The apparent discrepancy between receptor expres-
sion and function is likely due to the fact that receptor mRNA
does not equate to receptor function. In addition, expression
was studied in whole vessels so that we cannot distinguish
expression in endothelial cells from vascular smooth muscle
cells. P2 receptors in the vasculature are present on endothe-
lial cells as well as on vascular smooth muscle cells.
Activation of P2X1 receptors and, in some vascular beds,
P2X2, P2X4 and P2Y1, P2Y2, and P2Y6 receptors on smooth
muscle cells, generally results in vasoconstriction, although
vasodilation is sometimes also observed [39]. Activation of
P2Y1, P2Y2 and possibly also P2Y4, P2Y11, P2X1, P2X2,
P2X3, P2X4, and P2X7 receptors on endothelial cells leads
to the production of nitric oxide (NO) and subsequent vaso-
dilation [39, 40]. It is therefore possible that a shift in expres-
sion of the P2Y1 receptors from vascular smooth muscle to
endothelium may have resulted in an increased contribution
of these receptors to the vasodilator effect of Up4A.
Interestingly, with age, a shift in P2Y1 receptors from endo-
thelial cells to vascular smooth muscle cells was observed in
the rat cerebral vasculature [41]. Consistent with these find-
ings, we observed an attenuation of Up4A-induced vasorelax-
ation by P2Y1-receptor blockade in our previous study in
healthy swine of approximately 4 months of age [23] but
not in the present study in healthy swine of approximately
9 months of age. These findings also suggest that metabolic
derangement may have prevented this age-dependent shift
from endothelial to smooth muscle cell expression of P2Y1.
Future studies are needed to investigate the metabolic
disorder-induced changes in purinergic receptor subtype dis-
tribution between coronary endothelial and vascular smooth
muscle cells in more detail.
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Fig. 6 Involvement of
thromboxane in Up4A-induced
relaxation. Shown are
concentration responses to Up4A
(10−9–10−5 M) in the presence
and absence of 10 μM of the
thromboxane synthase inhibitor
ozagrel in porcine coronary small
arteries (normal (n = 5, panel a);
metabolic derangement (n = 4,
panel c)), as well as in the
presence of 100 μM of the NOS
inhibitor LNAME (normal (n = 6,
panel b); metabolic derangement
(n = 7, panel d)). Values are
mean ± SEM. *P < 0.05 effect of
ozagrel vs. corresponding control
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Metabolic derangement is accompanied by microvascular
dysfunction and a shift in the balance between endothelium-
derived vasodilators and vasoconstrictors [4, 5]. In the present
study, endothelial denudation blunted Up4A-induced relaxa-
tion in coronary small arteries from normal swine but not
swine with metabolic derangement. This effect of endothelial
denudation was similar to the effect of eNOS inhibition with
LNAME, indicating a reduced involvement of NO in the va-
sodilator response to Up4A in metabolic derangement.
Reduced eNOS activity, which is a hallmark of coronary en-
dothelial dysfunction in humans with metabolic derangement
[42], was also observed in our previous study in coronary
small arteries [3] and is consistent with the reduced eNOS
expression in swine with metabolic derangement observed in
the present study.
Endothelial dysfunction often results in a shift in produc-
tion of endothelium-derived vasodilators, e.g., from NO to
prostanoids and EDHF [43], and an increase in endothelium-
derived vasoconstrictors such as thromboxane [44, 45]. In the
present study, we found that inhibition of COX had no effect
in coronary small arteries from either normal swine or swine
with metabolic derangement while the thromboxane synthase
inhibitor ozagrel significantly enhanced the vasodilator re-
sponse to Up4A in the presence of eNOS inhibition in swine
with metabolic derangement but not in normal swine, consis-
tent with thromboxane production in response to Up4A.
However, although NO-production was reduced in the coro-
nary microvasculature of swine with metabolic derangement,
there was no effect of thromboxane synthase inhibition in
coronary small arteries with active eNOS, suggesting that
even in metabolic derangement, NO suppresses the produc-
tion of thromboxane. An increased contribution of thrombox-
ane to vascular contraction in response to Up4A was also re-
cently shown in renal arteries from type 2 diabetic rats, al-
though in that study the increased contribution of thrombox-
ane appeared to be due to an increased sensitivity rather than
an increased production of thromboxane [13]. However, in the
present study, constriction to the stable thromboxane mimetic
U46619 was not different between normal swine and swine
with metabolic derangement (data not shown), indicating that
sensitivity to thromboxane was not altered. A potential mech-
anism that has been proposed to underlie the increased throm-
boxane production in metabolic derangement is that low-
grade inflammation results in eNOS uncoupling, which sub-
sequently leads to the production of reactive nitrogen species
such as peroxinitrite, that is capable of inactivating PGI2-syn-
thase and cause a shift in production from prostacyclin to
thromboxane [44, 45].
EDHF has been demonstrated to compensate for the loss of
NO in metabolic disorder [46], and CYP 2C9 has been report-
ed to generate EETs that can act as an EDHF in the coronary
vasculature [47]. In addition to these vasodilator EETs, CYP
2C9 can also produce ROS [48], which act as vasoconstrictors
in the porcine coronary vasculature [49]. Although we have
previously shown in pre-adolescent swine that inhibition of
CYP 2C9 alone [15], or in the presence of inhibition of eNOS/
COX (unpublished data), does not affect Up4A-induced relax-
ation, we found in the present study in adult swine that inhi-
bition of CYP 2C9, in the presence of inhibition of eNOS and
COX, potentiated the vasodilator response to Up4A in coro-
nary small arteries from normal swine. These data are consis-
tent with the observations that CYP 2C9 activity increases
with age [50] but predominantly produces ROS in healthy
porcine coronary small arteries [48]. In contrast, in coronary
small arteries from swine with metabolic derangement, inhi-
bition of CYP 2C9 in the presence of eNOS- and COX-
inhibition reduced the vasorelaxation in response to Up4A,
suggesting that CYP 2C9 switches from the production of
vasoconstrictor to vasodilator metabolites in metabolic de-
rangement. Such production of vasodilator metabolites by
CYP 2C9 is consistent with other studies showing that CYP
2C9 metabolites can act as an EDHF [47] and that EDHF(s) is
able to compensate for the chronic loss of NO in coronary
vasculature in metabolic derangement [46].
In conclusion, while the overall vasodilator response to
Up4A was maintained in coronary small arteries of swine
with metabolic derangement, the purinergic receptor sub-
types as well as the EDVFs mediating this response were
markedly altered. These findings suggest the presence of
compensatory mechanisms among signaling pathways in
Up4A-mediated coronary vasomotor influences in the ear-
ly phase of metabolic derangement. Future studies are
warranted to investigate the effects of severe metabolic
derangement on coronary responses to Up4A.
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